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RESULTS: Approximately 10 studies matched the selec-
tion criteria, all published in 1994 or later. The safety mea-
sures evaluated were donor screening, viral inactivation of
frozen plasma, and single-donor versus random-donor
platelet collection. Cost-effectiveness ranged from cost sav-
ings for screening donors for hepatitis C antibodies, to sev-
eral million US$ per QALY gained as a result of screening
donors for HIV using p-24 or nucleic-acid tests. Cost-
effectiveness of viral inactivation of plasma and of shifting
to single-donor platelet collection strongly depends on the
patient population. For example, US$100,000-200,000
per QALY gained for coronary artery bypass graft and
US$400,000-500,000 for cancer patients.
CONCLUSIONS: In the USA and Canada, thresholds
for acceptable cost-effectiveness are US$50,000 and
Can$20,000-100,000 (US$13,000-67,000) per QALY
gained. For the Netherlands, the threshold has recently been
defined at Dfl40,000 per life-year gained (EUR18,000,
US$16,000). Preliminary results from our European
model applied to the recently introduced nucleic-acid
testing of Dutch donors for HIV indicate cost-effective-
ness ratios of US$100,000 per life-year gained and above.
Most cost-effectiveness ratios for interventions in trans-
fusion safety are beyond currently accepted thresholds
for cost-effectiveness. This may imply that different thresh-
olds for cost-effectiveness apply when making decisions
about the introduction of new technologies that enhance
transfusion safety.
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OBJECTIVES: Pharmaceutical expenditures in Greece in-
crease by approximately 18% annually. To curtail spend-
ing, government has recently cut prices and introduced a
positive drug list. The short-term impact of these mea-
sures led the government to propose new drug list criteria
and submission of pharmacoeconomic studies already
submitted in other countries for new products. We ad-
dress the current status of pharmacoeconomics research
and discuss future developments in Greece.
METHODS: We reviewed all available studies published
in Greek or English, to assess methodological problems.
We reviewed current developments in the public and pri-
vate sectors and policy documents to assess the potential
for future use of pharmacoeconomics in drug policy.
Case studies provide support for proposed conclusions.
RESULTS: Methodological quality is generally poor.
Cost minimization is the preferred technique although
differences in efficacy are not properly assessed. Few
studies accurately describe resource consumption and
costing methodologies. Modeling assumptions are weak,
due to absence of epidemiological and health-care utiliza-
tion data. Little emphasis is given to prospective clinical
studies. Thye societal perspective is rarely used—the
health system perspective prevails. Little experience exists
in QoL measurement and cost-utility techniques. Sensi-
tivity analyses are rarely performed. The pharmaceutical
industry is the major driving force for pharmacoeco-
nomic research despite minimal use in pricing and reim-
bursement decisions and weak endorsement by some. In-
dustry use is mainly for supporting marketing and sales
strategies. The government is hesitant to apply pharma-
coeconomics widely in pricing and reimbursement due to
perceived lack of expertise despite disappointment with
pricing controls. Recent health-care reforms may alter
current mindset. Medical professionals are increasingly
receptive of pharmacoeconomics research but place little
value on modeling approaches.
CONCLUSIONS: Pharmacoeconomics in Greece must
improve methodological standards. This is a task for
both industry and government. Wider application in pric-
ing and reimbursement is a still a matter for debate.
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OBJECTIVE: Companies producing innovative products
typically terminate all advertising and promotion (A&P)
of branded products once generics have been launched.
This may be prudent since branded sales often decline by
50% to 75% in the first year following generic introduc-
tion. Our primary hypothesis was that companies, which
cease A&P on products about to be genericized, might in-
directly hasten the decline in sales of branded products by
increasing the relative share of the competitors’ promo-
tional activity. We further hypothesized that this alter-
ation in A&P may result in a shift to more expensive
competitive compounds, thereby negating any savings re-
alized from the generic compound.
METHODS: Three therapeutic categories (selective sero-
tonin re-uptake inhibitors (SSRIs), anti-lipidemics [statins]
and anti-ulcer compounds) were selected for a compre-
hensive analysis of sales data.
RESULTS: A trend towards an increase in growth of
competitive, branded compounds, following the introduc-
tion of a generic drug, appeared to be true for both statins
and SSRIs. Aggregate fluoxetine sales and/or reimburse-
ments declined significantly in Ontario (18.5%), Que-
bec (34.9%) and nationally (42.8%) following the in-
troduction of generic fluoxetine. Although the overall
category growth for SSRIs was 49.2%, 117.0% and
97.5% for Ontario, Quebec and Canada respectively,
during the same time period, both paroxetine and sertra-
line experienced a much faster growth rate. Following the
introduction of generic lovastatin, aggregate lovastatin
sales and/or reimbursement declined 39.0% in Ontario,
32.4% in Quebec and 40.1% nationally. Coincidentally
